The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia-Reference-Cited by-同舟云学术

The prognostic potential of monitoring disease dynamics in NPM1-positive acute myeloid leukemia

Published:2019-01-23 Issue:6 Volume:33 Page:1531-1534
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hoffmann H.,Thiede C.,Glauche I.^ORCID,Kramer M.,Röllig C.,Ehninger G.,Bornhäuser M.,Roeder I.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0371-y.pdf

Reference10 articles.

1. Schuurhuis GJ, Heuser M, Freeman S, Béné M-C, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275–91.

2. Ivey A, Hills RK, Simpson MA, Jovanovic JV, Gilkes A, Grech A, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;11:e9.

3. Shayegi N, Kramer M, Bornhäuser M, Schaich M, Schetelig J, Platzbecker U, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122:83–92.

4. Schnittger S, Kern W, Tschulik C, Weiss T, Dicker F, Falini B, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood. 2009;114:2220–31.

5. Krönke J, Schlenk RF, Jensen K-O, Tschürtz F, Corbacioglu A, Gaidzik VI, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol. 2011;29:2709–16.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable Residual Disease Assessment in Pediatric AML;Pediatric Oncology;2024

2. Heliangin acts as a covalent ligand of RPS2 that disrupts pre-rRNA metabolic processes in NPM1-mutated acute myeloid leukemia;Acta Pharmaceutica Sinica B;2023-02

3. How to predict relapse in leukemia using time series data: A comparative in silico study;PLOS ONE;2021-11-15

4. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial;Blood Cancer Journal;2021-06

5. Overlooking the obvious? On the potential of treatment alterations to predict patient-specific therapy response;Experimental Hematology;2021-02